DE-LYCRA
26.7.2022 14:02:28 CEST | Business Wire | Press release
The LYCRA Company , a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, today announced a partnership with Browzwear that will provide designers using VStitcher and Lotta, the pioneering platforms for 3D fashion design, the ability to quickly and easily develop products incorporating fabrics containing LYCRA®, LYCRA® T400®, and COOLMAX® fibers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005001/en/
The partnership with Browzwear is the latest element of a multifaceted digital transformation that The LYCRA Company began last year with the launch of the LYCRA ONE™ customer portal, an online marketplace connecting brands, retailers, and garment makers to a global network of partner mills in a virtual capacity. The expansion of The LYCRA Company’s digital infrastructure is enabling new forms of engagement with its global customer base, and online platforms, like Browzwear, demonstrate the differentiation and sources of innovation that The LYCRA Company is helping bring to its customers across the apparel value chain.
With the true-to-life visualizations made possible with Browzwear's innovative software, the industry's leading 3D software for apparel design and development, designers can digitally create activewear, denim, swimwear, ready-to-wear, and intimate apparel fashions using fabrics showcased in the LYCRA® Brand Materials Library. The Browzwear platform enables designers to visualize how garments made with LYCRA® fiber offer a comfortable, lasting fit that will move with the wearer.
All the materials with digital versions in the LYCRA® Brand Materials Library can be sourced directly from one of 15 global mills initially featured on Browzwear. These materials have been tested and certified by The LYCRA Company, ensuring they contain the company’s authentic fibers that are designed to meet consumer needs for comfort, fit and ease of movement. In addition, The LYCRA Company will continue to work with Browzwear to add new resources to the materials library as they become available, further enhancing the digital design capabilities.
This partnership also advances The LYCRA Company’s sustainability commitment to offering a variety of fiber and fabric solutions that reduce or divert waste and keep materials in use longer. Creating digital garments via Browzwear streamlines the production process and reduces the need to manufacture samples, saving time and reducing waste for more efficient and sustainable operations.
“At The LYCRA Company, innovation is in our DNA, and we constantly look at new ways to create value for our mill customers, brands, and retail partners," said Julien Born, CEO of The LYCRA Company. "Digital transformation and sustainability offer opportunities, but also stretch our approach to innovation as fast and meaningful advances in those areas cannot be achieved alone. By teaming up with Browzwear, we are taking an important step in that direction, with the goal of ultimately changing the way the apparel industry will engage and interact digitally to optimize the sourcing of high-quality fabrics that extend garment wear life and reduce the need for samples.”
" We are thrilled to collaborate with The LYCRA Company and enable our users to leverage its well-known performance fibers to better incorporate them into designs, faster, easier, and more sustainably. Our Fabric Analyzer ensures the 3D versions of fabrics made with fibers from the LYCRA® Brand Materials Library result in true-to-life simulations of the garments, with physics and movement that reflect the durability and unique functionality of these fibers,” said Avihay Feld, Browzwear co-founder and CEO. “We believe this partnership will drive positive impact throughout the industry by helping brands and retailers to operate a more sustainable, efficient development process."
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA® , LYCRA HyFit® , LYCRA® T400® , COOLMAX® , THERMOLITE® , ELASPAN® , SUPPLEX® , and TACTEL® . The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
LYCRA® and COOLMAX® are trademarks of The LYCRA Company.
About Browzwear
Founded in 1999, Browzwear is a pioneer of 3D digital solutions for the fashion industry, driving seamless processes from concept to commerce. For designers, Browzwear accelerates collection development, opening limitless opportunities to create iterations of styles. For technical designers and pattern makers, Browzwear rapidly fits graded garments with accurate, true-motion material replication. For manufacturers, Browzwear’s Tech Pack delivers everything needed to produce physical garments perfectly the first time, and at every step from design to production. Worldwide, more than 650 organizations such as Columbia Sportswear, PVH Group and VF Corporation leverage Browzwear’s open platform to streamline processes, collaborate and pursue data-driven production strategies so they can sell more while manufacturing less, which increases both ecologic and economic sustainability. For more information, visit www.browzwear.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
